Summary

for people ages 45-99 (full criteria)
at Sacramento, California and other locations
study started
estimated completion
Nasim Hedayati, Dr.

Description

Summary

This will be a randomized, placebo-controlled, parallel group, multicenter, Phase III study.The study aims to evaluate the Efficacy, Tolerability and Safety of Intramuscular Injections of PLX PAD for the Treatment of Subjects with Critical Limb Ischemia (CLI) with Minor Tissue Loss (Rutherford Category 5) who are Unsuitable for Revascularization.

Official Title

Efficacy, Tolerability and Safety of Intramuscular Injections of PLX PAD for the Treatment of Subjects With Critical Limb Ischemia (CLI) With Minor Tissue Loss Who Are Unsuitable for Revascularization

Keywords

Critical Limb Ischemia (CLI) Ischemia PLX-PAD

Eligibility

You can join if…

Open to people ages 45-99

  1. Adult male or female subjects between ages 45-99 years of age.
  2. CLI, with minor tissue loss up to the ankle level (Rutherford Category 5)
  3. Ankle pressure (AP) ≤70 mmHg or TP ≤50 mmHg in the index leg. (If a subject has ABI >1.4 and TP is not measureable, inclusion may be based on TcPO2 ≤30 mmHg)
  4. Subject unsuitable for revascularization (by any method) in the index leg.
  5. Ischemic lesions in the index leg stable for at least 2 weeks.
  6. Ischemic ulcers in the index leg without tendon or bone exposure (unless secondary to a minor amputation).
  7. Under treatment for cardiovascular risk factors: hypertension, hyperlipidemia, diabetes, in accordance with applicable guidelines. Concomitant therapy with a statin and an anti-platelet agent for at least 2 weeks prior to randomization.
  8. Women of childbearing potential must have a negative serum pregnancy test at screening and must be willing to use at least one highly effective birth control method throughout the study.
  9. Signed informed consent form.

You CAN'T join if...

  1. Non-atherosclerotic PAD (e.g. Buerger's disease).
  2. CLI with major tissue loss (Rutherford Category 6) in either leg.
  3. Evidence of active infection (e.g., cellulitis, osteomyelitis).
  4. Subject having undergone surgical revascularization or major amputation less than 1 month prior to screening, or endovascular revascularization or minor amputation less than 2 weeks prior to screening.
  5. Planned or potential need for major/minor amputation or any revascularization within 1 month of study entry upon investigator's judgment.
  6. Aorto-iliac stenosis or common femoral artery stenosis ≥70%, or otherwise suspicion of inadequate inflow to the leg.
  7. Life expectancy of less than 6 months.
  8. Stroke or acute myocardial infarction/unstable angina within 3 months prior to screening.
  9. Severe congestive heart failure symptoms (New York Heart Association [NYHA] Stage IV).
  10. . Uncontrolled severe hypertension.
  11. . Diabetes mellitus with HbA1c >10%.
  12. . Current or history of proliferative retinopathy.
  13. . Known Hepatitis B virus or Hepatitis C virus or acquired immunodeficiency syndrome (AIDS) infections.
  14. . Subjects with international normalized ratio (INR) >2.5.
  15. . Subject on renal replacement therapy or with eGFR <15 mL/min/1.73m2.
  16. . Subject is currently enrolled in, or has not yet completed a period of at least 30 days since ending another investigational device or drug trial(s), unless in long-term follow-up phase.
  17. . Use of hyperbaric oxygen therapy, prostanoids, spinal cord stimulation, lumbar sympathectomy, wound dressing containing cells or growth factors, or topical platelet derived growth factor.
  18. . Known allergies to any of the following: DMSO, human serum albumin, bovine serum albumin.
  19. . History of allergic/hypersensitivity reaction to any substance having required hospitalization and/or treatment with IV steroids/epinephrine.
  20. . Pulmonary disease requiring supplemental oxygen treatment on a daily basis.
  21. . Active malignancy or history of malignancy within 5 years prior to study entry.
  22. . In the opinion of the investigator, the subject is unsuitable for participating in the study.
  23. . Inability to understand and provide an informed consent.

Locations

  • Vascular Center ∣ Department of Surgery ∣ UC Davis Health 4860 Y street, Sacramento, CA suite #3400, 95817 accepting new patients
    Sacramento California 95817 United States
  • Vascular Center,Department of Surgery,UC Davis Health,4860 Y street accepting new patients
    Sacramento California 95817 United States

Lead Scientist

  • Nasim Hedayati, Dr.
    Associate Professor, Surgery. Authored (or co-authored) 34 research publications.

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Pluristem Ltd.
Links
Sign up for this study
ID
NCT03006770
Phase
Phase 3
Study Type
Interventional
Last Updated